Thermo Fisher Scientific has agreed to partner with Novartis and Pfizer to develop and commercialize a next-generation sequencing oncology test to serve as a companion diagnostic for non-small cell lung cancer across multiple drug development programs.

The test will be developed using Thermo Fisher’s Ion PGM Dx system and Oncomine assays.

Financial terms of the deal were not disclosed. — Michael Cipriano